By Wayne Kuznar San Diego, CA—Rheumatology nursing is in its infancy but is evolving rapidly as demand increases for modern services and new complex medications require skilled providers to administer and manage them, said Kori A. Dewing, DNP, ARNP, Rheumatology Nurse Practitioner, Virginia Mason Medical Center, Seattle, WA, at the 2013 American College of Rheumatology meeting.
By Wayne Kuznar San Diego, CA—Subcutaneous clazakizumab, an investigational monoclonal antibody against interleukin (IL)-6, was found to be effective with or without methotrexate in adults with moderate-to-severe active rheumatoid arthritis (RA) who have an inadequate response to methotrexate at key end points, according to a phase 2b study presented at the 2013 American College of Rheumatology (ACR) meeting.
By Alice Goodman San Diego, CA—A low-tech, inexpensive, slip-on knee brace reduces pain and joint damage associated with osteoarthritis (OA), according to a study presented at the 2013 American College of Rheumatology meeting. This is the first study to quantify the effect of a knee brace on pain and joint damage in patients with OA, according to the authors.
By Phoebe Starr San Diego, CA—“This is an exciting time for treatment of rheumatoid arthritis [RA], with many new therapies. But the question is where do we go from here for future therapies, and what have we learned from past failures,” Arthur F. Kavanaugh, MD, Director, Center for Innovative Therapy, University of California, San Diego, La Jolla, told listeners at the 2013 American College of Rheumatology meeting.
Although patient survival has improved, systemic lupus erythematosus (SLE) remains associated with significant morbidity and mortality. As part of a continuation study of a phase 2 clinical trial, investigators sought to determine the disease control and safety profile of belimumab with standard therapy in patients with SLE and found that when administered with standard therapy, it was safe and maintained disease control (Ginzler EM, et al. J Rheumatol. 2014;41:300-309).
By Wayne Kuznar San Diego, CA—Biologic response modifiers for the treatment of patients with rheumatoid arthritis (RA) do not appear to offset healthcare costs over 3 years, according to an econometric analysis presented at the 2013 American College of Rheumatology meeting. The finding comes from a population-based cohort of more than 700 patients with RA in British Columbia, Canada, identified from an administrative database.
By Wayne Kuznar San Diego, CA—Although health insurance benefit plans often include “step-therapy” policies that aim at limiting the use of specialty pharmaceuticals (eg, infused biologics), which often are costly, such policies often do not achieve this goal, according to a study presented at the 2013 American College of Rheumatology meeting by Michael P. Ingham, MSc, Department of Health Economics & Outcomes Research–Immunology, Janssen Scientific Affairs, Horsham, PA, and colleagues.
By Phoebe Starr San Diego, CA—CT-P13 showed 2-year efficacy and safety equivalent to that of infliximab (Remicade) in patients with rheumatoid arthritis (RA) on assessments of disease activity and safety, according to a study presented at the 2013 American College of Rheumatology (ACR) meeting.
By Wayne Kuznar San Diego, CA—Developments in therapeutics for rheumatoid arthritis (RA) have been taking place at breathtaking speed. Biologic agents have greatly increased the ability to improve the lives of patients with RA, and integrating their use with conventional agents will lead to optimal patient outcomes, said Ronald van Vollenhoven, MD, PhD, at the Rational Approach to Treating RA symposium presented during the 2013 American College of Rheumatology (ACR) meeting. Expect additional biologic agents, biosimilars, and oral agents with efficacies comparable to biologics, he said.
Page 1 of 2
Results 1 - 10 of 20
Results 1 - 10 of 20